FA
ELGX

Friess Associates’s Endologix Inc ELGX Stock Holding History

Friess Associates’s Portfolio ELGX Stock Details ELGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-6,000
Closed -$748K – 169
2016
Q2 		$748K Hold
6,000
– – 0.08% 80
2016
Q1 		$502K Hold
6,000
– – 0.05% 108
2015
Q4 		$594K Buy
+6,000
New +$643K 0.06% 99

Other funds holding ELGX

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Friess Associates's ELGX Position: Q3 2016 in Review

Friess Associates sold out of Endologix Inc (ELGX) in Q3 2016, closing a stake of 6,000 shares — an estimated $748K sold.

Friess Associates first reported a position in ELGX in Q4 2015 and held it in 3 quarters. The position peaked at $748K in Q2 2016. 152 funds tracked by Wall St. Rank hold ELGX as of Q3 2016.

  • Friess Associates reported no remaining Endologix Inc position as of Q3 2016 after selling out during the quarter.
  • Friess Associates sold 6,000 Endologix Inc shares in Q3 2016, an estimated $748K.
  • Friess Associates first reported a position in Endologix Inc in Q4 2015 and held it in 3 quarters.
  • Friess Associates's Endologix Inc position peaked at $748K in Q2 2016.
  • 152 funds tracked by Wall St. Rank held Endologix Inc as of Q3 2016.

Based on Friess Associates's 13F filing for Q3 2016, filed 14 Nov 2016.